United States-based Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced on Tuesday positive initial results from an ongoing Phase three clinical trial assessing REGEN-COV (casirivimab and imdevimab antibody cocktail) used as a passive vaccine intended for the prevention of COVID-19 in people at high risk of infection (due to household exposure to a COVID-19 patient).
The company is jointly running the trial in collaboration with The National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH).
The firm conduced an exploratory analysis on the first around 400 assessable individuals enrolled in the trial, who were randomised to receive passive vaccination with REGEN-COV (1,200mg via subcutaneous injections) or placebo. Passive vaccination resulted in 100% prevention of symptomatic infection and around 50% lower overall rates of infection.
Regeneron is collaborating with Roche to increase global supply of REGEN-COV.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer